Introduction
In modern medicine, it is common practice to treat many diseases concurrently with several drugs that target multiple biological targets via different mechanisms of action in order to achieve the desirable therapeutic outcome concertedly. To this end, an increasing number of clinically established drugs are reformulated to give a fixed-dose dual-component medicine as an alternative to co-administering the agents as two individual drugs. While this approach is an obvious choice for attaining a combined therapy, an attractive and more elegant strategy is to design a single drug that inhibits more than one biological target. In fact, the design of single agents that act against multiple biological targets is of increasing interest and prominence. In recent years, an increasing volume of work has been published exemplifying the successful use of this strategy. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] Breast cancer is a devastating disease that affects many women from different age groups. When the disease is first diagnosed, about two-thirds of cases are classified as hormonedependent, in which the growth and development of tumours are fuelled by oestrogens. Endocrine therapy is an effective form of treatment for breast cancer of this type. The current gold standard for treating patients with hormone-dependent breast cancer is a selective oestrogen receptor modulator (SERM) such as tamoxifen, which blocks the action of oestrogens on the oestrogen receptor. In addition, the inhibition of aromatase, which leads to a decrease in the biosynthesis of oestrogens, is well established as an effective form of endocrine treatment for breast cancer. The three aromatase inhibitors (AIs) currently in clinical use for treating patients with advanced hormone-dependent breast cancer (HDBC) are letrozole, anastrozole, and exemestane. Various clinical trials in the last decade have even advocated the use of these AIs in an earlier clinical setting for treating primary breast cancer. [12] [13] [14] [15] [16] [17] [18] However, inhibition of aromatase is not the only strategy available for decreasing the production of oestrogens. There is evidence that inhibition of steroid sulfatase (STS), the enzyme that converts the biologically inactive oestrone sulfate to oestrone, [19] may render significant oestrogen deprivation in patients treated with an STS inhibitor. The nonsteroidal compound 1 (STX64, Irosustat, Figure 1 ) is the first STS inhibitor entered into clinical trials. [20, 21] Because both aromatase and STS are involved in the synthesis of biologically active oestrogens, it has been reasoned that concurrent inhibition of these two enzymes in patients with HDBC may lead to a more comprehensive oestrogen deprivation and hence a better response to endocrine therapy. Our research group has pioneered the approach of designing dual aromatase and sulfatase inhibitors (DASIs) as a single agent for inhibiting aromatase and STS concurrently. To date, we have developed five structural classes of nonsteroidal DASIs. Briefly: 1) derivatives of the nonsteroidal AI 4-{(4-bromobenzyl)- [1, 2, 4] triazol-4-ylamino}benzonitrile (e.g., 2-5, Figure 1 ); [22] [23] [24] [25] 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated (F, Cl, Br) derivatives are first-generation dual aromatase and sulfatase inhibitors (DASIs). Structure-activity relationship studies were performed on these compounds, and various modifications were made to their structures involving relocation of the halogen atom, introduction of more halogen atoms, replacement of the halogen with another group, replacement of the methylene linker with a difluoromethylene linker, replacement of the para-cyanophenyl ring with other ring structures, and replacement of the triazolyl group with an imidazolyl group. The most potent in vitro DASI discovered is an imidazole derivative with IC 50 values against aromatase and steroid sulfatase in a JEG-3 cell preparation of 0.2 and 2.5 nm, respectively. The parent phenol of this compound inhibits aromatase with an IC 50 value of 0.028 nm in the same assay.
2) derivatives of letrozole (e.g., 6, Figure 1) ; [26] [27] [28] 3) derivatives of anastrozole (e.g., 7, Figure 1) ; [29] 4) derivatives based on a biphenyl template (e.g., 8, Figure 1) ; [30] and 5) a series of compounds with a hybrid structure of experimental DASIs (e.g., 9, Figure 1 ). [31] Herein we report the further expansion of the series of DASIs 2-5. Inhibitory activities of new candidates against aromatase and STS were evaluated in JEG-3 cells, and structure-activity relationships (SAR) are discussed.
Results and Discussion

Chemistry
The preparation of 4-[(4-cyanophenyl)amino]-4H-1,2,4-triazole (10, Scheme 1) was carried out according to Okada et al. [32] All of the novel sulfamates and phenols described herein were prepared according to the schemes described below. The final compounds and intermediates were characterised by standard analytical methods, and the purity of the compounds tested in vitro was evaluated by HPLC.
The synthesis of sulfamates 11-13, 17-19 is outlined in Scheme 1. Following formation of the requisite benzyl alcohols 11 b, 12 a, 13 b, 17 a, 18 b, the final three steps of the synthesis were identical for each of the sulfamates. The appropriate benzyl alcohol was converted into the corresponding benzyl chloride with thionyl chloride, and this was allowed to react with 10 in N,N-dimethylformamide (DMF) in the presence of potassium carbonate to give phenols 11 c, 12 b, 13 c, 17 c, and 18 d, respectively. The phenols were converted into their corresponding sulfamates with excess sulfamoyl chloride according to the conditions described by Okada et al. [33] Benzyl alcohols 11 b and 13 b were obtained from 2-fluoro-and 2,3-difluoro-4-hydroxybenzoic acids, respectively, following conversion into their methyl esters (with methanol/cat. HCl for 11 b and methanol/SOCl 2 for 13 b) and reduction of these with lithium aluminium hydride in tetrahydrofuran. From 2,6-difluoro-4-hydroxybenzoic acid, benzyl alcohol 12 a was obtained directly following reduction with LiAlH 4 in THF.
For the synthesis of compound 19, 3-bromo-4-methylphenol was protected as the benzoate 19 a and subsequently brominated with N-bromosuccinimide (NBS) under radical conditions ((BzO) 2 The route to sulfamate 14 starting from diethyl-2-(2,6-difluoro-4-methoxyphenyl)malonic acid, [34] which was itself synthesised by the reaction of diethyl malonate with 4-bromo-3,5-difluoroanisole, is shown in Scheme 2. The diester was hydro- Figure 1 . Structures of nonsteroidal steroid sulfatase inhibitor 1 (STX64, Irosustat) and various structural classes of dual aromatase-sulfatase inhibitor (DASI) 2-9; X= OSO 2 NH 2 .
Scheme 1. Synthesis of compounds 11-13 and 17-19. Reagents and conditions: a) MeOH, HCl (cat.), reflux, 78 %; b) LiAlH 4 , THF, RT, 76-94 %; c) SOCl 2 , MeOH, reflux, 100 %; d) NaBH 4 , EtOH/H 2 O, RT, 93 %; e) SOCl 2 , RT; f) 10, K 2 CO 3 , DMF, RT, 15-100 %; g) H 2 NSO 2 Cl, DMA, 0 8C!RT, 55-95 %; h) BzCl, py, RT, 75 %; i) NBS, (BzO) 2 , CCl 4 , reflux, 51 %; j) 10, NaH, DMF, RT, 85 %; k) KOH, MeOH, 52 %.
lysed to diacid 14 a with 3 m sodium hydroxide, and this decarboxylated following heating at 160 8C to give 14 b. The acid was converted into methyl ester 14 c, and the phenol was demethylated following treatment with boron tribromide in dichloromethane and then re-protected with triisopropylsilyl chloride (TIPSCl) to furnish 14 e. The methyl ester was reduced with LiAlH 4 to give alcohol 14 f, which was converted into the corresponding bromide following treatment with PPh 3 /CBr 4 in dichloromethane. This was subsequently used to alkylate the sodium hydride generated anion of 10. Removal of the TIPS protecting group was achieved with tetra-n-butylammonium fluoride (TBAF) in THF, and the resulting phenol 14 h was converted into sulfamate 14 under the conditions previously described.
Sulfamate 15 was prepared in seven steps (Scheme 3) from 3-formyl-4-hydroxybenzoic acid methyl ester 15 a, which was prepared from methyl 4-hydroxybenzoate as described by Hofsløkken and Skattebol. [35] Starting material 15 a was fluorinated with Deoxo-Fluor to give phenol 15 b, which was then TIPSprotected to furnish 15 c. Reduction of the ester was successfully achieved with lithium borohydride, and the resulting benzyl alcohol was converted into the corresponding benzyl bromide with phosphorus tribromide in dichloromethane. This was subsequently used to alkylate the sodium hydride generated anion of 10 to furnish 15 f. Removal of the TIPS protecting group was carried out with TBAF in THF, and the resulting phenol 15 g was converted into sulfamate 15 under the conditions previously described.
Sulfamate 16 was prepared from 4-benzyloxybenzoic acid according to the route illustrated in Scheme 4. Following preparation of the acid chloride with thionyl chloride, reaction with 10 gave amide 16 a. The amide was converted into the corresponding thioamide with Lawesson's reagent in xylenes at reflux, and this was fluorinated with Deoxo-Fluor in the presence of catalytic antimony trichloride to give 16 c. [36] Deprotection of the phenol was achieved by catalytic hydrogenation with palladium on charcoal to give 16 d, and the formation of the corresponding sulfamate was achieved using the conditions previously described to give 16. The trio of sulfamates 20, 21, and 22 were prepared according to the route described in Scheme 5 by starting from commercially available aniline, 5-amino-2,2-difluoro-1,3-benzodioxole, and 3,5-difluoroaniline, respectively. Each amine was condensed with 4-benzyoxybenzaldehyde to give imines 20 a, 21 a, and 22 a, which were subsequently reduced with sodium borohydride to give amines 20 b, 21 b, and 22 b. The triazole ring was constructed stepwise, firstly by treating the requisite amines with sodium nitrite and then with LiAlH 4 to give hydrazines 20 c, 21 c, and 22 c. This was followed by treatment of the hydrazines with dimethylformamide diazine dihydrochloride in pyridine at reflux [37] to furnish 20 d, 21 d, and 22 d. The benzyl group was removed by catalytic hydrogenation with palladium on charcoal, and finally the phenol was sulfamoylated under the conditions described above to give compounds 20, 21, and 22.
The synthesis of compound 25 is shown in Scheme 6. 4-(1H-Imidazol-1-ylamino)benzonitrile (24) was prepared in two steps following a patent procedure. [38] Commercially available 4-cyanophenylhydrazine hydrochloride was allowed to react with 2-isothiocyanato-1,1-dimethoxyethane in acetic acid and water at 100 8C to give 23, which was then treated with hydrogen peroxide in acetic acid to afford 24. The benzyl chloride 25 b was obtained by converting 11 b into the benzyl ether 25 a and subsequent treatment of 25 a with thionyl chloride in dichloromethane. Benzyl chloride 25 b was used to alkylate the sodium hydride generated anion of 24 to afford 25 c. The benzyl group of 25 c was removed by catalytic hydrogenation with palladium on charcoal, and finally the phenol 25 d was converted into sulfamate 25 by using the conditions described above.
Biological assays
The in vitro inhibition of aromatase and STS activity by each sulfamate was measured in a preparation of an intact monolayer of JEG-3 cells. The results are reported as IC 50 values and are compared with those of published data for DASIs 2-5 ( Table 1) . We also tested the in vitro inhibition of aromatase by parent phenols in the same manner. The results are listed in Table 2 and are compared with published data for compounds 2 a-5 a.
1) Sulfamates
Although their potency against an individual enzyme is not as high as that observed for the single agent AI letrozole (IC 50 = 0.89 nm, JEG-3), [25] and STS inhibitor 1 (IC 50 = 1.5 nm, JEG-3), [23] reference compounds 2-5 are first-generation DASIs that show significant dual inhibition against aromatase and STS. A preliminary SAR study for these compounds established, among other things, that a halogen atom substituted at the ortho position to the sulfamate group contributes significantly to the biological activities observed for these compounds and that the sulfamate group positioned para to the methylene linker between the arylsulfamate motif and the 4-(4H-1,2,4-triazol-4-ylamino)benzonitrile moiety is crucial for potent STS inhibition. [23] The SAR for this class of DASIs is further expanded in this work. The first modification made to DASIs 3, 4, and 5 was the relocation of their halogen atom from the ortho to the meta position to the sulfamate group to give derivatives 11 (m-fluoro), 17 (m-chloro), and 19 (m-bromo), respectively. As shown in Table 1 , this modification decreases the ability of the derivatives to inhibit aromatase (fluorinated derivatives: 3, IC 50 = 12 nm vs. 11, IC 50 = 39 nm; chlorinated derivatives: 4, IC 50 = 2.3 nm vs. 17, IC 50 = 18 nm; brominated derivatives: 5, IC 50 = 0.82 nm vs. 19, IC 50 = 2.6 nm). These results suggest that substitution of a single halogen atom on the sulfamate-bearing phenyl ring in this class of DASIs is more effective for inhibiting aromatase if it is made at the ortho position to the sulfamate group. Like the ortho-halogenated derivatives 3, 4, and 5, the fluoro derivative 11 is less potent than the chloro derivative 17, which in turn is a weaker AI than the bromo derivative 19. This ascending order of potency against aromatase observed might be related to the increase in lipophilicity of the compounds as the size of the halogen increases from fluorine to bromine. The relocation of a halogen from the ortho to the meta position to the sulfamate group does not affect the STS inhibitory activity significantly, as meta-halogenated compounds 11, 17, and 19 inhibit STS to a similar extent as their 50 values ranging between 20 and 44 nm. We have demonstrated repeatedly in previous SAR studies that the STS inhibitory activity of an aryl sulfamate can generally be increased by lowering the pK a value, and hence improving the leaving group ability, of its parent phenol. [22-25, 27-31, 39] Because of the electron-withdrawing effect on the sulfamate group exerted by the halogens at the m,m'-position, the pK a values of parent phenols 12 b and 18 c are predicted to be between 0.4 and 1.0 log units lower than those of phenols 3 a, 4 a, 11 c, and 17 c (as calculated by ACD/Labs v11.02 and based on comparison between respective mono-and dihalogenated para-cresols). The fact that 12 and 18 are not more effective STS inhibitors than 3, 4, 11, and 17, as predicted, suggests their STS inhibitory activities observed might be influenced by other factors.
c) o,m-Difluorinated derivative 13
When the two fluoro atoms are substituted on the same side of the phenyl ring at the ortho and meta positions to the sulfamate group, the resulting derivative 13 (o-F, m-F, IC 50 = 7 nm) inhibits aromatase about fivefold less effectively than 12 (m-F, 50 value of 100 pm against STS in a placental microsome preparation. [40] It was reasoned that the electron-withdrawing effect of the 2-fluoromethyl group, as well as the potential of the fluorine atoms to form hydrogen bonds with residues lining the catalytic active site of STS, are contributive factors to the high potency observed. To explore the effect of the difluoromethyl group on the STS and aromatase inhibitory activity of this class of DASIs, the ortho-fluoro atom of 3 was replaced with a difluoromethyl group. As shown in Table 1 , the difluoromethyl group improves aromatase inhibition, as 15 (IC 50 arom. = 4.4 nm) is threefold more potent than 3 as an AI. However, contrary to expectation, there is no apparent improvement on STS inhibition observed with 15, showing an IC 50 value of 60 nm against STS, compared with 40 nm for 3. It is possible that the more flexible structure of this class of DASIs, in contrast to the more rigid backbone of a steroidal STS inhibitor, does not align the 2-difluoromethyl group effectively for favourable interactions within the STS active site. e) Derivatives with an ethylene linker (14) and a difluoromethylene linker (16) When the methylene linker between the arylsulfamate motif and the 4-(4H-1,2,4-triazol-4-ylamino)benzonitrile moiety of 12 was replaced by an ethylene group, such an extension decreases both the aromatase and STS inhibitory activities of the resulting derivative 14, with the potency against STS more significantly impaired (12, IC 50 arom. = 1.3 nm, IC 50 STS = 39 nm vs. 14, IC 50 arom. = 4 nm, IC 50 STS = 485 nm). A similar adverse effect on STS inhibition is observed when the methylene linker of 2-5 is replaced by either an ethylene or a propylene group; in contrast, however, a much improved or at least similar inhibition of aromatase was observed for the ethylene derivatives of 2-5. [24] In addition to elongating the methylene linker of 12, the methylene linker of 2 was replaced with difluoromethylene to give 16. We reasoned that this electron-withdrawing motif would, on the one hand, lower the pK a of the parent phenol 16 d and hence improve the ability of sulfamate 16 to inhibit STS; on the other hand, the two fluoro atoms should increase the lipophilicity of the derivative and hence make a relative improvement of the aromatase inhibition by 16 (clog P 0.875, cf. 0.179 for 12, as calculated by ChemBioDraw Ultra v12.0.2). However, against some expectations, this modification significantly decreases the inhibitory activity of 16 (IC 50 arom. = 1013 nm, IC 50 STS = 190 nm) against aromatase, but acts to maintain a level of STS inhibition similar to that observed for 2 (IC 50 arom. = 100 nm, IC 50 STS = 227 nm). These results suggest that the difluoromethylene motif is tolerated by STS, but not by aromatase, when it replaces the methylene group as the linker between the aryl sulfamate motif and the 4-(4H-1,2,4-triazol-4-ylamino)benzonitrile moiety. f) Replacement of the para-cyanophenyl ring of 2 with other entities (20, 21, and 22) After varying the substitution pattern of halogens on the sulfamate-bearing aryl ring and modifying the alkylene linker in this class of compounds, the para-cyanophenyl ring of 2 was modified first by replacing its para-cyano group with a hydrogen atom to give 20, and then by replacing the ring altogether with a 3,5-difluorophenyl ring or a 2,2-difluorobenzo[d]- [1, 3] dioxol-5-yl moiety to give 21 and 22, respectively.
As shown in Table 1 , replacement of the cyano group of 2 with a hydrogen atom is clearly detrimental to dual inhibitory activity. The IC 50 values of 20 for aromatase (2483 nm) and STS (1557 nm) inhibition are an order of magnitude higher than those observed for 2 (IC 50 arom. = 100 nm, IC 50 STS = 227 nm). A previous SAR study on nonsteroidal AIs that are based on a biphenyl template (e.g., 8, Figure 1 ) demonstrated that a cyano group substituted at the position on the phenyl ring para to a haem-ligating moiety, such as the triazolylmethyl group, is important for potent aromatase inhibition. [41] Either the removal of the cyano group or the replacement of it with a fluorine or a chlorine atom leads to derivatives that are significantly weaker AIs. [41] Docking studies on this class of biphenyl-based AIs into a homology model of human aromatase (PDB code: 1TQA) revealed that the cyano group might interact favourably with Ser478 of the active site through hydrogen bond interactions. [41] In addition to its positive effect on aromatase inhibition, the para-cyano group is apparently also important for STS inhibition, as 20 is some sevenfold weaker as an inhibitor than 2. It is possible that the para-cyano group of 2 functions as a hydrogen bond acceptor and interacts favourably with amino acid residue(s) lining the enzyme active site of STS, allowing a better binding affinity of 2 to the enzyme active site than 20.
Replacement of the para-cyanophenyl group of 2 with a 3,5-difluorophenyl ring or a 2,2-difluorobenzo[d] [1, 3] dioxol-5-yl moiety produces much weaker AIs, although the ability of 21 (IC 50 = 760 nm) to inhibit aromatase is better than that of 22 (IC 50 = 4060 nm), suggesting that the 3,5-difluorophenyl ring interacts better with the aromatase active site than the 2,2-difluorobenzo[d] [1, 3] dioxol-5-yl moiety. However, both 21 (IC 50 = 45 nm) and 22 (IC 50 = 52 nm) are more potent STS inhibitors, with activities an order of magnitude higher than that of 2 (IC 50 = 227 nm). These results suggest that while the 3,5-difluorophenyl ring and the 2,2-difluorobenzo[d] [1, 3] dioxol-5-yl moiety do not improve aromatase inhibition, they confer favourable properties to 21 and 22 for a stronger binding of the compounds to the active site of STS. From this SAR study, it can be concluded that the para-cyanophenyl ring provides the best balanced dual inhibition for this class of DASIs.
g) Imidazole derivative 25
The most potent DASI studied in this work is compound 25, the respective IC 50 values of which against aromatase and STS are 0.2 and 2.5 nm. Compared with 11 (IC 50 arom. = 39 nm, IC 50 STS = 21 nm), the replacement of its triazole moiety with an imidazole to give 25 improves both the aromatase and STS inhibitory activities by two orders and one order of magnitude, respectively. (Note: In their patent application, Lafay et al. cited compounds of similar structural features which also possess potent dual inhibition of aromatase and STS.) [38] The increase in aromatase inhibition observed for 25 is not unexpected, as imidazole (pK BH + = 7.0) is a stronger Lewis base than a triazole (pK BH + = 2.2). The lone-pair electrons on the sp 2 nitrogen atom of an imidazole are more readily available for ligating to the haem iron centre than the equivalent in a triazole. Therefore, with other structural features being the same, it is anticipated that an imidazole-containing AI will inhibit aromatase more strongly than its triazole-containing counterpart.
To explore how 25 may interact with the active site of aromatase, we docked the compound and its triazole congener 11 into the crystal structure of human aromatase that had been co-crystallised with androstenedione. [42, 43] Like previous docking studies performed for structurally similar AIs, a distance constraint was set between the haem iron and the ligating nitrogen atom in this work. As shown in Figure 2 , the preferred docking poses of 25 (yellow) and 11 (pink) are similar with their heterocycles position under the haem. One small difference observed is that the imidazole group of 25 is 0.1 further away from the haem than the triazole group of 11. This is probably due to steric hindrance posed by the CH group of the imidazole ring of 25 preventing the heterocycle from approaching closer to the iron. The sulfamate group of both 11 and 25 points towards Ser478 and Asp309. Hydrogen bonds (within 2.5-2.6 ) are anticipated between the sulfamate nitrogen atom and the backbone carbonyl group of Asp309, and also between one of the sulfamate oxygen atoms and the side chain hydroxy group of Ser478. The cyano group of both compounds points towards the same region of space as the C17 carbonyl group of androstenedione, where it may interact with the backbone NH of Met374 as a hydrogen bond acceptor. These docking results of 11 and 25 show the two compounds could potentially bind to active site of aromatase and interact with neighbouring amino acid residues, although the preferred docking poses observed cannot explain the superior aromatase inhibition observed for 25.
For STS inhibition, 25 is a potent inhibitor in JEG-3 cells (IC 50 = 2.5 nm) with potency similar to that of STS inhibitor 1 (IC 50 = 1.5 nm). However, it is not evident why replacing the triazolyl group with an imidazole renders such a significant increase in STS inhibition over that observed for 11. The docking of 11 and 25 into the crystal structure of human STS [44] does not reveal any significant difference in their poses. As shown in Figure 3 , 11 and 25 bind similarly to STS. Their sulfamate groups interact with FGly75, His290, Lys368, and the calcium ion, whereas their cyano groups point towards the guanidinium group of Arg98. The phenyl ring to which their cyano group is attached may have a face-edge interaction with the ring of Phe488. Despite their different orientations in the docking poses, the imidazole of 25 and the triazole of 11 share the same region of space and may form hydrogen bonds with one or both of Gly100 and Thr99.
Despite the relatively high in vitro potency observed for AIs that contain an imidazole group as the haem-ligating species, it is worth noting that all nonsteroidal AIs currently in clinical use are solely triazole derivatives. Although to the best of our knowledge the preference in featuring a triazole over an imidazole as the haem-ligating species is not clear, one possibility is that triazole compounds are metabolically more stable than their imidazole counterparts in vivo. [45] It is also possible that triazole-containing aromatase inhibitors are more selective against inhibiting aromatase, whereas imidazole-containing compounds show a wider inhibitory profile against other cytochrome P450 enzymes in addition to aromatase.
2) Parent phenols
We reason that the parent phenols of DASIs can act as AIs in their own right because they possess the minimum pharmacophore for inhibiting aromatase, that is, a haem-ligating moiety such as a triazole or an imidazole. In vivo, at least until all the STS is inhibited, the parent phenol is anticipated to be the immediate product released after irreversible inactivation of STS by an aryl sulfamate according to the various mechanisms of action proposed by our group. [19, [46] [47] [48] In addition, the parent phenol may also be released if the sulfamate group is hydrolytically cleaved in the plasma due to the limited chemical stability observed for some sulfamates (which increases as the phenolic pK a is lowered). Therefore, the parent phenols of all new sulfamates studied in this work were also assessed for their ability to inhibit aromatase.
Previous SAR studies have shown that parent phenols are generally more potent than their corresponding aryl sulfamates as aromatase inhibitors. In this work, however, only 11 c Table 2) .
Relocation of a halogen atom from the ortho to the meta position to the hydroxy group has little effect on aromatase inhibition, as shown by the similar activities observed for 3 a (IC 50 = 2.9 nm) vs. 11 c (IC 50 = 3.9 nm), 4 a (IC 50 = 2.5 nm) vs. 17 c (IC 50 = 3 nm), and 5 a (IC 50 = 1.1 nm) vs. 19 d (IC 50 = 1.1 nm). In contrast, sulfamates 11, 17, and 19 are significantly weaker AIs than 3, 4, and 5 respectively.
While adding a second fluoro atom to the remaining meta position of 11 c (IC 50 = 3.9 nm) to give the m,m'-difluorinated compound 12 b (IC 50 = 1.3 nm) improves aromatase inhibition by about threefold, the m,m'-chlorinated compound 18 c (IC 50 = 2.3 nm) shows similar aromatase inhibitory activity to its m-chlorinated counterpart 17 c (IC 50 = 3 nm). These results contrast those of sulfamates 12 and 18, which are both significantly better AIs than 11 and 17. Table 2 . In vitro inhibition of aromatase activity in a JEG-3 cell preparation by parent phenols described in this work; compounds 2 a-5 a are included as reference. [23] Compd
Aromatase IC 50 [nm]
Similar to their sulfamates, the o,m-difluorinated compound 13 c (IC 50 = 6.7 nm) is a weaker AI than its m,m'-difluorinated counterpart 12 b (IC 50 = 1.3 nm). This result supports the previous observation that disubstitution of fluorine atoms is more effective for aromatase inhibition if they are substituted at the m,m'-position rather than at the o,m-position on the sulfamate-bearing ring.
Replacing the methylene linker of 12 b (IC 50 = 1.3 nm) with an ethylene linker improves the aromatase inhibitory activity of the resulting compound 14 h (IC 50 = 0.14 nm) by nearly tenfold. This observation is not unprecedented, as a similar finding was observed when the methylene linkers of 2 a-5 a were replaced with an ethylene linker. [24] Replacing the ortho-fluorine atom of 3 a (IC 50 = 2.9 nm) with a difluoromethyl group only leads to a moderate increase in potency against aromatase in the resulting compound 15 g (IC 50 = 1.52 nm). In contrast, difluorination of the methylene linker of 2 a (IC 50 = 23 nm) is clearly detrimental to aromatase inhibition, as shown by thẽ 13-fold decrease in aromatase inhibitory observed for 16 d (IC 50 = 297 nm).
Like their sulfamate counterparts, the replacement of the para-cyanophenyl ring of 2 a with a phenyl, 3,5-difluorophenyl, or 2,2-difluorobenzo[d] [1, 3] dioxol-5-yl ring is detrimental to aromatase inhibition. The phenols 20 e, 21 e, and 22 e have IC 50 values two orders of magnitude higher than that of 2 a.
The most potent in vitro AI in this work is the imidazole derivative 25 d (IC 50 = 0.028 nm) which is about sevenfold more potent than its corresponding sulfamate 25 (IC 50 = 0.2 nm) and three orders of magnitude more potent than the triazole counterpart 11. In addition, the IC 50 value of 25 d against aromatase in JEG-3 cells is an order of magnitude higher than that of letrozole (IC 50 = 0.89 nm) obtained from the same intact cell assay. However, it is yet to be demonstrated whether this exceptionally high in vitro potency of 25 d can be reproduced in vivo when the efficacy of a drug is affected by various pharmacokinetic parameters.
Conclusions
Modifications made to first-generation DASIs 2-5 produce mixed results. The SAR for the sulfamates is generalised in Figure 4 . For STS inhibition, all derivatives show similar STS inhibitory activities unless the para-cyanophenyl ring is replaced with a phenyl ring, and the methylene linker is elongated to an ethylene linker or replaced with a difluoromethylene group, where a large decrease in potency is observed. There is a higher degree of variation in the aromatase inhibitory activities observed for the sulfamates, although the most detrimental modifications are replacement of the methylene linker with an ethylene linker, and replacement of the para-cyanophenyl ring with a phenyl, 3,5-difluorophenyl, or 2,2-difluorobenzo[d]- [1, 3] dioxol-5-yl ring. The most potent DASI discovered in this work is the imidazole derivative 25, with IC 50 values against aromatase and STS in JEG-3 cells similar to those of letrozole and 1 (STX64, Figure 1 ), respectively, obtained from the same assay. The exceptionally potent aromatase inhibition observed for 25 can be attributed to a stronger ligation of its imidazole sp 2 nitrogen atom to the iron of the haem group than the equivalent in a triazole. Docking of 11 and 25 into the crystal structure of human aromatase shows the two compounds share a similar docking pose. Similarly, docking of the two compounds into the crystal structure of human STS reveals that 11 and 25 share a similar binding mode in the active site.
The parent phenols of the sulfamates are good to potent AIs, although replacing the methylene linker with a difluoromethylene group as well as replacing the para-cyanophenyl ring with a phenyl, 3,5-difluorophenyl, or 2,2-difluorobenzo[d]- [1, 3] dioxol-5-yl ring significantly decreases the aromatase inhibitory activities of the resulting derivatives. As expected, the most potent AI is the imidazole derivative 25 d. The SAR for the phenols is generalised in Figure 5 .
The present work further demonstrates the ability of this structural class of compounds to act as DASIs. Although there is no general breakthrough in designing compounds that ex- hibit more potent dual inhibition in vitro, interestingly, if the triazole group is replaced by an imidazole as the haem-ligating species, significant activity enhancement is observed both for aromatase and dual aromatase-sulfatase inhibition. The synthesis of more imidazole-containing DASIs is therefore warranted, although to establish real potential for drug design, the in vivo activities of these compounds need to be assessed in parallel in order to evaluate their metabolic stability as well as selectivity towards aromatase inhibition.
Experimental Section
In vitro aromatase and sulfatase assays: Biological activities were performed essentially as described previously. [23] The extent of in vitro inhibition of aromatase and sulfatase activities was assessed using intact monolayers of JEG-3 human choriocarcinoma cells, which were chosen because these cells constitutively express both enzymes maximally. Aromatase activity was measured with [1b- , PerkinElmer Life Sciences, MA, USA) over a 1 h period. Sulfatase activity was measured using [6, H]E1S (50 Ci mmol À1 , PerkinElmer) over a 1 h period.
Molecular modelling: The 3EQM crystal structure of aromatase [42, 43] and the 1P49 crystal structure of sulfatase [44] were used for docking studies. They were passed through the Protein Preparation Wizard of the Schrçdinger software platform. GOLD [49] was used to dock the ligands into both substrate binding sites. [NB: Four new crystal structures of aromatase have recently been released: [50] 3S79 (with androstenedione) is effectively identical to the 3EQM structure, 3S7S (with exemestane), and 4GL5 and 4GL7, which both have Olinked alkyl chains attached to the 6-position of the steroid ring.]
For aromatase the binding site was centred on the crystal structure ligand (androstenedione) and required the centroid of the docked ligand to be within 5 of the androstenedione centroid. A distance constraint of 2.3 was applied between the ligating nitrogen atom of the triazole or imidazole ring and the haem iron atom.
For sulfatase the sulfate group was removed from residue formylglycine sulfate 75 (FGS75) to leave a gem-diol form of formylglycine residue. The centroid of the docked ligand was required to be within 5 of the calcium ion in the substrate binding site. No constraints were applied during the docking.
General methods for synthesis: All chemicals were purchased from either Aldrich Chemical Co. (Gillingham, UK) or Alfa Aesar (Heysham, UK). All organic solvents of analytical reagent grade were supplied by Fisher Scientific (Loughborough, UK). Anhydrous N,N-dimethylformamide (DMF), N,N-dimethylacetamide (DMA) and tetrahydrofuran (THF) were purchased from Aldrich. Sulfamoyl chloride was prepared by an adaptation of the method of Appel and Berger [51] and was stored as a solution under N 2 in toluene as described by Woo et al. [46] Thin-layer chromatography (TLC) was performed on pre-coated aluminium plates (Merck, silica gel 60 F 254 ). Product spots were visualised either by UV irradiation at l 254 nm or by staining with either an alkaline solution of KMnO 4 or 5 % w/v dodecamolybdophosphoric acid in EtOH, followed by heating. Flash column chromatography was performed on silica gel (Davisil silica 60A) or prepacked columns (Isolute), and gradient elution (solvents indicated in text) on either the Flashmaster II system (Biotage) or on a Teledyne ISCO CombiFlash R f Automated Flash Chromatography System with RediSep R f disposable flash columns. General method A-hydrogenation: Pd/C was added to a solution of the substrate in the solvents indicated. The solution was stirred under an atmosphere of H 2 (provided by addition from a balloon) overnight. The excess H 2 was removed, and the reaction mixture was filtered through Celite washing with THF and MeOH, then the solvent was removed in vacuo.
General method B-sulfamoylation: A solution of sulfamoyl chloride (H 2 NSO 2 Cl) in toluene was concentrated in vacuo at 30 8C to furnish a yellow oil which solidified upon cooling in an ice bath. DMA and the substrate were subsequently added, and the mixture was allowed to warm to room temperature and stirred overnight. in MeOH (100 mL) was heated at reflux for 12 h. The mixture was allowed to cool and was neutralised with sat. aq. NaHCO 3 . The solvent was removed in vacuo, and the residue was dissolved in EtOAc (100 mL) and washed with H 2 O (100 mL), sat. aq. NaHCO 3 (100 mL), and brine (100 mL), then dried (MgSO 4 3,5-Difluoro-4-(hydroxymethyl)phenol (12 a): 2,6-Difluoro-4-hydroxybenzoic acid (0.50 g, 2.87 mmol) was cautiously added to a suspension of LiAlH 4 (0.55 g, 14.5 mmol) in THF (20 mL). The resulting mixture was stirred at reflux for 24 h. After cooling to room temperature, the reaction was quenched by the cautious addition of EtOAc (10 mL) and then H 2 O (10 mL). A further portion of EtOAc (50 mL) was added and the layers were separated. The aqueous layer was extracted with EtOAc (50 mL) and the combined organic layers were washed with 3 m aq. HCl (2 50 mL), then dried (MgSO 4 ) and the solvent was removed in vacuo to give title compound as a white solid (0.40 g, 87 %): 
4-{[(4-
)(4H-1,2,4-triazol-4-yl)amino]methyl}-2,3-difluorophenyl sulfamate (13): As general method B using ClSO 2 NH 2 (0.6 m, 3.4 mL), DMA (3 mL) and 13 c (0.11 g, 0.34 mmol). The crude product was purified using Flashmaster II (CH 2 Cl 2 /acetone) to give the title compound as an amorphous white solid (0.14 g, 95 %); 2-(2,6-Difluoro-4-methoxyphenyl)malonic acid (14 a): 3m aq. NaOH (80 mL) added to a solution of diethyl 2-(2,6-difluoro-4-methoxyphenyl)malonate (synthesised according to a patented procedure; [34] 6.30 g, 20.85 mmol) in Et 2 O (5 mL). The reaction mixture was heated at reflux until all the solid had dissolved. After cooling, the mixture was acidified with 3 m aq. HCl and the product was extracted with EtOAc (2 100 mL). The combined organic layers were dried (MgSO 4 ) and solvent was removed in vacuo to give the title compound as a tan-coloured solid ( 21 .0 mmol) and triisopropylsilyl chloride (TIPSCl, 2.24 g, 11.6 mmol) were sequentially added to a paleyellow solution of 14 d (2.13 g, 10.5 mmol) in DMF (10 mL). The reaction mixture was stirred overnight, then poured onto H 2 O (40 mL) and extracted with EtOAc (3 50 mL). The combined organics were washed with H 2 O (3 100 mL) and brine (100 mL), then dried (MgSO 4 ) and the solvent was removed in vacuo. The crude product was purified using the CombiFlash system (PE/ EtOAc) to give the title compound as a colourless oil (3.43 g, 91 %); www.chemmedchem.org the sequential addition of EtOAc (25 mL), H 2 O (25 mL) and 3 m HCl (25 mL). The product was extracted with EtOAc (2 75 mL) and the combined organic layers were washed with sat. aq. NaHCO 3 (2 100 mL) dried (MgSO 4 ) and the solvent was removed in vacuo. The crude product was purified using the CombiFlash system (EtOAc/ PE) to give the title compound as a colourless oil (1.70 3-Formyl-4-hydroxybenzoic acid methyl ester (15 a): This compound was prepared according to the method described by Hofsløkken and Skattebol; [35] yield = 38 %. CHEMMEDCHEM FULL PAPERS www.chemmedchem.org NaHCO 3 (sat., 10 mL) and CH 2 Cl 2 (30 mL) were added and the layers were separated. The organic layer was washed with H 2 O (2 50 mL) and brine (50 mL) then dried (MgSO 4 ) and the solvent was removed in vacuo. The solvent was removed in vacuo, and the crude product was purified using Flashmaster II (EtOAc/hexane) to give the title compound as a white crystalline solid (0.58 g, 76 %): mp: 43-45 8C; Benzyloxy-N-(4-cyanophenyl)-N-[1,2,4 ]triazol-4-ylbenzamide (16 a): A suspension of 4-benzyloxybenzoic acid (1.00 g, 4.39 mmol) in SOCl 2 (10 mL) was heated at reflux until gas evolution ceased and was then allowed to cool and SOCl 2 was removed in vacuo. The residue was suspended in CH 2 Cl 2 (40 mL) and 10 (0.65 g, 3.51 mmol) and Et 3 N (3.55 g, 35.1 mmol) were sequentially added and the mixture was stirred for 2 h. The reaction mixture was concentrated in vacuo and the residue was dissolved in EtOAc (60 mL) and washed with 1 m aq. HCl (60 mL), H 2 O (60 mL), NaHCO 3 (60 mL) and brine (60 mL). The organic layer was dried (MgSO 4 ) and the solvent was removed in vacuo. The crude product was purified using Flashmaster II (EtOAc/hexane) to give the title compound as a white crystalline solid (0. 
4-
3-Chloro-4-(hydroxymethyl)phenol (17 a):
This was prepared according to the method described by Matysiak et al.; [52] yield = 14 %. 6 m, 3 mL), DMA (3 mL) and 17 c (0.12 g, 0.37 mmol) . The crude product was purified using Flashmaster II (EtOAc/hexane) and was then precipitated from EtOAc/hexane to give the title compound as a white amorphous solid (0.12 g, 81 2,6-Dichloro-4-hydroxybenzaldehyde (18 a): This was prepared according to the method as described by Bringmann et al. [53] 3,5-Dichloro-4-(hydroxymethyl)phenol (18 b): A solution of NaBH 4 (0.070 g, 1.84 mmol) in H 2 O (0.5 mL) was added dropwise to a solution of 18 a (0.13 g, 0.68 mmol) in EtOH (2 mL). After stirring for 1 h, the reaction was quenched by the cautious addition of aq. HCl (3 m, 5 mL), EtOAc (10 mL) and H 2 O (10 mL). The layers were separated and the aqueous was extracted with EtOAc (10 mL). The organic layers were combined, washed with H 2 O (2 20 mL) and aq. (3 30 mL) . The combined organic layers were washed with sat. aq. NaHCO 3 (60 mL) and brine (60 mL) then dried (MgSO 4 ) and the solvent was removed in vacuo. The crude product was purified using the CombiFlash system (CH 2 Cl 2 /acetone) to give the title compound as a white solid (0.14 g, 52 53 mmol) in THF (50 mL) and EtOH (50 mL). The mixture was allowed to warm to room temperature and stirring was continued for 18 h. The reaction mixture was poured into H 2 O (250 mL) and the products were extracted with EtOAc (3 100 mL). The combined organic layers were washed with H 2 O (100 mL) and brine (50 mL), dried (MgSO 4 ) and concentrated under reduced pressure. The residue was dissolved in CHCl 3 and passed through a short SiO 2 column (~5 cm). The volatiles were removed in vacuo and the residue was recrystallised from CHCl 3 /PE to afford the title compound as fine colourless needles (5 (40 mL) . The mixture was stirred for 0.5 h and then the organic layer was separated, washed with brine (20 mL), dried (Na 2 SO 4 ) and concentrated in vacuo. The residue was dissolved in THF (30 mL) and added to a suspension of LiAlH 4 (1.44 g, 37.9 mmol) in THF (10 mL). The reaction mixture was stirred overnight at room temperature, then H 2 O (2 mL) and 5 m NaOH (3 mL) were added carefully. The inorganic salts were filtered off and washed with THF, the organic fraction was dried over Na 2 SO 4 and the volatiles were removed in vacuo. The residue was purified using the CombiFlash R f (CH 2 Dimethylformamide diazine dihydrochloride [37] (7.07 g, 32.86 mmol) was added to a solution of 20 c (5.00 g, 16.43 mmol) in pyridine (10 mL) and the mixture was heated at reflux for 2 h. After cooling to room temperature EtOAc (60 mL) and H 2 O (30 mL) were added, the organic layer was separated, washed with 2 m KHSO 4 solution (2 30 mL) and brine (30 mL), dried (Na 2 SO 4 ) and concentrated under reduced pressure. The residue was recrystallised from MeOH to afford the title compound as pale-yellow plates (3.12 g, 53 %): mp: 165-167 8C; (20 mL) . The mixture was stirred for 1 h and then the organic layer was separated, washed with brine (20 mL), dried (Na 2 SO 4 ) and concentrated in vacuo. The residue was dissolved in THF (20 mL) and added to a suspension of LiAlH 4 (0.25 g) in THF (30 mL). The reaction mixture was stirred overnight at room temperature, then H 2 O (2 mL) and 5 m NaOH (3 mL) were added carefully. The inorganic salts were filtered off and washed with THF, the organic fraction was dried over Na 2 SO 4 and the volatiles were removed in vacuo. The residue was purified by flash column chromatography (CHCl 3 ) to afford the title compound as a white solid (2.45 
